Literature DB >> 27561082

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

Mykola Pinkevych, Deborah Cromer, Martin Tolstrup, Andrew J Grimm, David A Cooper, Sharon R Lewin, Ole S Søgaard, Thomas A Rasmussen, Stephen J Kent, Anthony D Kelleher, Miles P Davenport.   

Abstract

[This corrects the article DOI: 10.1371/journal.ppat.1005000.][This corrects the article DOI: 10.1371/journal.ppat.1005740.][This corrects the article DOI: 10.1371/journal.ppat.1005679.].

Entities:  

Year:  2016        PMID: 27561082      PMCID: PMC4999226          DOI: 10.1371/journal.ppat.1005745

Source DB:  PubMed          Journal:  PLoS Pathog        ISSN: 1553-7366            Impact factor:   6.823


There are errors in the data analysis of several patients in cohort 4, interruption 1, that affect the reactivation rate for cohort 4 reported in the Results section and Fig 4.
Fig 4

Time-to-detection of virus in cohorts 3 and 4.

(A) time-to-detection in cohort 3, of 18 patients undergoing interruption (reference [16]). The best-fit frequency of reactivation is once every 5.1 days. (B) time-to-detection in cohort 4, of 14 patients undergoing five interruptions, and monitored at days 4, 8, and 14 (reference [17]). The best-fit frequency over all interruptions is once every 6.3 days. (C) Time to recrudescence is not correlated with growth rate in cohort 3. (D) Higher reactivation rates in SIV than HIV. The estimated frequency of initiation of viral replication in SIV infected macaques treated with ART between 7 and 14 days post-infection (from reference [26]) is shown as solid line, and was found to be once every 1.7 days. The best-fit frequency of reactivation across the four HIV cohorts (a reactivation event every 6 days) is shown as a dashed line.

Time-to-detection of virus in cohorts 3 and 4.

(A) time-to-detection in cohort 3, of 18 patients undergoing interruption (reference [16]). The best-fit frequency of reactivation is once every 5.1 days. (B) time-to-detection in cohort 4, of 14 patients undergoing five interruptions, and monitored at days 4, 8, and 14 (reference [17]). The best-fit frequency over all interruptions is once every 6.3 days. (C) Time to recrudescence is not correlated with growth rate in cohort 3. (D) Higher reactivation rates in SIV than HIV. The estimated frequency of initiation of viral replication in SIV infected macaques treated with ART between 7 and 14 days post-infection (from reference [26]) is shown as solid line, and was found to be once every 1.7 days. The best-fit frequency of reactivation across the four HIV cohorts (a reactivation event every 6 days) is shown as a dashed line. The data for cohort 4 was extracted from Fig 1A of reference 17. This involves 14 individuals undergoing 5 sequential treatment interruptions. Data for time-to-detection after treatment interruption for cohort 4 of our paper (displayed in Fig 4B) was extracted directly from this table. Patients who had detectable virus at the time of interruption (for any given interruption) were excluded from analysis in that interruption. Unfortunately in interruption 1, patients were accidentally excluded if they had detectable HIV at the time of interruption for any of the five interruptions (instead of being excluded only if they had detectable HIV in the first interruption). Thus, instead of 14 patients that should have recorded a time-to-detection in interruption 1, 6 patients were wrongly excluded (patients 109, 112, 116, 125, 127, 129) and only 8 patients were included in this analysis for interruption 1. In interruptions 2 to 5, patients were correctly excluded. The inclusion of these additional 6 patients for interruption 1 alters the best estimate of frequency of reactivation for cohort four from once every 7.2 days to once every 6.3 days. We note that inclusion of interruption 1 for these 6 patients does not affect the average rate of reactivation over all patients in the four cohorts (once every 6.0 days), as this only affects one reading in 6 out of 100 patients analyzed. The number 7.2 should be changed to 6.3 days in the fourth sentence of the second paragraph and last sentence of the last paragraph of the subsection "HIV reactivation in other cohorts", as well as in the Fig 4B legend. Please find the corrected Fig 4 here. This error does not affect the conclusions of the paper.
  1 in total

1.  HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

Authors:  Mykola Pinkevych; Deborah Cromer; Martin Tolstrup; Andrew J Grimm; David A Cooper; Sharon R Lewin; Ole S Søgaard; Thomas A Rasmussen; Stephen J Kent; Anthony D Kelleher; Miles P Davenport
Journal:  PLoS Pathog       Date:  2015-07-02       Impact factor: 6.823

  1 in total
  6 in total

1.  HIV-1 latent reservoir size and diversity are stable following brief treatment interruption.

Authors:  D Brenda Salantes; Yu Zheng; Felicity Mampe; Tuhina Srivastava; Subul Beg; Jun Lai; Jonathan Z Li; Randall L Tressler; Richard A Koup; James Hoxie; Mohamed Abdel-Mohsen; Scott Sherrill-Mix; Kevin McCormick; E Turner Overton; Frederic D Bushman; Gerald H Learn; Robert F Siliciano; Janet M Siliciano; Pablo Tebas; Katharine J Bar
Journal:  J Clin Invest       Date:  2018-06-18       Impact factor: 14.808

2.  Plasmacytoid dendritic cells sense HIV replication before detectable viremia following treatment interruption.

Authors:  Julie L Mitchell; Hiroshi Takata; Roshell Muir; Donn J Colby; Eugène Kroon; Trevor A Crowell; Carlo Sacdalan; Suteeraporn Pinyakorn; Suwanna Puttamaswin; Khunthalee Benjapornpong; Rapee Trichavaroj; Randall L Tressler; Lawrence Fox; Victoria R Polonis; Diane L Bolton; Frank Maldarelli; Sharon R Lewin; Elias K Haddad; Praphan Phanuphak; Merlin L Robb; Nelson L Michael; Mark de Souza; Nittaya Phanuphak; Jintanat Ananworanich; Lydie Trautmann
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

3.  Filgotinib suppresses HIV-1-driven gene transcription by inhibiting HIV-1 splicing and T cell activation.

Authors:  Yang-Hui Jimmy Yeh; Katharine M Jenike; Rachela M Calvi; Jennifer Chiarella; Rebecca Hoh; Steven G Deeks; Ya-Chi Ho
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

Review 4.  The Lymph Node in HIV Pathogenesis.

Authors:  Yiannis Dimopoulos; Eirini Moysi; Constantinos Petrovas
Journal:  Curr HIV/AIDS Rep       Date:  2017-08       Impact factor: 5.071

5.  HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.

Authors:  Timothy J Henrich; Hiroyu Hatano; Oliver Bacon; Louise E Hogan; Rachel Rutishauser; Alison Hill; Mary F Kearney; Elizabeth M Anderson; Susan P Buchbinder; Stephanie E Cohen; Mohamed Abdel-Mohsen; Christopher W Pohlmeyer; Remi Fromentin; Rebecca Hoh; Albert Y Liu; Joseph M McCune; Jonathan Spindler; Kelly Metcalf-Pate; Kristen S Hobbs; Cassandra Thanh; Erica A Gibson; Daniel R Kuritzkes; Robert F Siliciano; Richard W Price; Douglas D Richman; Nicolas Chomont; Janet D Siliciano; John W Mellors; Steven A Yukl; Joel N Blankson; Teri Liegler; Steven G Deeks
Journal:  PLoS Med       Date:  2017-11-07       Impact factor: 11.069

Review 6.  The Glutamate System as a Crucial Regulator of CNS Toxicity and Survival of HIV Reservoirs.

Authors:  Anna Maria Gorska; Eliseo A Eugenin
Journal:  Front Cell Infect Microbiol       Date:  2020-06-24       Impact factor: 5.293

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.